ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2017

Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers.

H A Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.